Frontage Laboratories is a contract research organization headquartered in Exton, Pennsylvania, founded in 2001 and incorporated in Pennsylvania in 2004.[S1][S3][S10] It is an organization listing eleven US laboratory addresses across seven metropolitan areas: eleven laboratory addresses across seven metropolitan areas, covering bioanalysis, drug metabolism, toxicology, genomics, chemistry, formulation and a Phase I clinical unit.[S4] A programme can move from discovery pharmacology through good laboratory practice toxicology to first-in-human dosing without leaving the group.[S5][S6][S8] Ownership runs offshore, however, and that is worth stating at the outset: the American company is a subsidiary of a holding company listed in Hong Kong, whose ultimate parent is Hangzhou Tigermed, a clinical research organization listed in China.[S10]
Services relevant to US drug developers
Bioanalysis and drug metabolism
Bioanalysis covers small and large molecules through chromatography with mass spectrometry, ligand binding assays, flow cytometry and immunogenicity testing, supporting pharmacokinetic and toxicokinetic studies, drug interaction work, bioavailability and bioequivalence, protein binding and biomarkers.[S6] The company states that good laboratory practice quantitative mass spectrometry is provided from five named sites, two of them in the United States and three outside it.[S6] Drug metabolism work includes radiolabelled studies, quantitative whole-body autoradiography, human mass balance studies with carbon-14, metabolite identification, cytochrome P450 interaction and permeability and transporter assays.[S7] Sponsors requiring radiolabeled or mass balance work should confirm the study type, site, isotope controls and regulatory scope in the proposal, and for a programme that needs it, it often determines the choice of laboratory.
Toxicology and discovery pharmacology
Toxicology runs from pilot and non-regulated studies through to pivotal studies supporting an investigational new drug application and a new drug application, and the company states that all standard dosing regimens and species are supported, including nonhuman primates.[S5] Discovery pharmacology is offered separately, with subcutaneous and orthotopic tumour xenograft models, metabolic disease models covering diabetes and obesity, inflammation and autoimmune models, behavioural models, transgenic animals, in vivo imaging and pharmacokinetic and pharmacodynamic relationship work.[S8] Efficacy results in these models describe the model; they do not establish clinical benefit.
Sites and how they were assembled
Several listed sites and capabilities entered the group through acquisitions documented in the company history, and knowing which site came from where helps in scoping a study. The Ohio toxicology and agrochemical site was Concord Biosciences, acquired in 2018; the Chicago toxicology site was Experimur, acquired in 2022; the Florida genomics site was Ocean Ridge Biosciences, acquired in 2021; the California chemistry site was ACME Biosciences, acquired in 2020; and a Toronto operation, Nucro-Technics, was acquired in 2023.[S3][S11] Four addresses in Exton cover headquarters and drug metabolism, biologics and biomarkers with chemistry and manufacturing controls, a further chemistry and manufacturing site, and a product development and manufacturing site.[S4] The Phase I clinical facility is in Secaucus, New Jersey.[S4]
Ownership and corporate structure
The chain is set out in the group own regulatory filing. Frontage Laboratories, Inc. is the United States operating company. Its parent, Frontage Holdings Corporation, is incorporated in the Cayman Islands and has been listed on the main board of the Hong Kong exchange since May 2019. The immediate holding company above that is Hongkong Tigermed, and the ultimate holding company is Hangzhou Tigermed Consulting.[S10] Group revenue for the first half of 2026 was about 148.2 million United States dollars, up 17.1 percent year on year, with the United States and Canada accounting for about 101.6 million of it.[S10] Headcount is stated as 1,800 at June 30, 2026, of whom 829 were in North America and Europe.[S10] The company homepage separately displayed a higher figure on September 3, 2026[S1]; the filed number is used here because it is dated and reported. Leadership changed in January 2025, when the chief executive moved to a science and strategy role and two co-chief executives were appointed.[S12]
Quality, compliance, and animal welfare (as stated by the company)
Good laboratory practice compliance is claimed for toxicology and for bioanalysis.[S5][S6] The company's website does not name a specific GLP regulation (FDA 21 CFR Part 58, EPA 40 CFR Part 160/792, or OECD GLP) for its facilities.[S5] GLP compliance is determined study by study under the applicable regulation, so sponsors should confirm in the protocol which regulation their study will follow and that the final report will carry the study director's compliance statement and the quality assurance unit's statement.[R2] The quality page states that the company lists FDA, DEA, CDC, Health Canada, Chinese authorities, the European Union and the World Health Organization under a combined inspections and approvals statement, without mapping any agency to a specific site or study type, the Drug Enforcement Administration, the Centers for Disease Control and Prevention, Health Canada, the Chinese authority, the European Union and the World Health Organization, and the homepage cites more than 200 FDA inspections in total.[S1][S9] Being inspected is not an approval or certification of the laboratory.[R6] An ISO quality certification is stated for the acquired Toronto operation specifically, not for the group.[S11]
One absence is worth flagging plainly, because of the scale of the animal work described. No AAALAC accreditation, USDA registration, Animal Welfare Assurance or reference to an institutional animal care and use committee was found on the company website, including its quality assurance page, across the pages reviewed.[S9] For an organization that states it runs good laboratory practice toxicology in standard species including nonhuman primates,[S5] sponsors should obtain site-specific documentation directly. It does not follow that the credentials are absent, only that they were not found on the site. AAALAC International accreditation is a voluntary evaluation of an institution's animal care and use program, re-evaluated every three years,[R3] and USDA registration and an OLAW Animal Welfare Assurance relate to the Animal Welfare Act and the PHS Policy respectively;[R4][R5] none of these establishes GLP compliance, which applies to individual studies.[R2] FDA does not approve or certify laboratories; registration with FDA does not denote approval.[R6] A sponsor placing animal work should ask for the registration and assurance numbers of the specific facility that will run the study, and confirm them with the issuing bodies.
Company facts
Operating company
Frontage Laboratories, Inc., incorporated in Pennsylvania on April 21, 2004[S10]
Headquarters
700 Pennsylvania Drive, Exton, PA 19341, United States[S1]
Frontage Holdings Corporation, Cayman Islands, listed on the Hong Kong exchange since May 2019[S10]
Ultimate parent
Hangzhou Tigermed Consulting, through Hongkong Tigermed[S10]
Employees
1,800 group-wide at June 30, 2026, of whom 829 in North America and Europe[S10]
Revenue
About 148.2 million US dollars for the six months to June 30, 2026, of which about 101.6 million in the United States and Canada[S10]
US sites
Eleven addresses: four in Exton, Pennsylvania, plus Secaucus, New Jersey; Concord, Ohio; Chicago, Illinois; Deerfield Beach, Florida; two in Hayward and one in Palo Alto, California[S4]
Services
Bioanalysis, DMPK including radiolabelled and mass balance work, discovery pharmacology, GLP toxicology, genomics, chemistry, formulation and Phase I clinical[S5][S6][S7][S8]
Species
Standard species including nonhuman primates, as stated by the company[S5]
GLP
Claimed; no specific regulation named on the pages reviewed[S5]
AAALAC, USDA, OLAW, IACUC
No statement found on the pages reviewed, including the quality assurance page
Inspections cited
FDA, DEA, CDC, Health Canada, the Chinese authority, the European Union and WHO; more than 200 FDA inspections cited in total[S1][S9]
FDA ? "Is It Really FDA Approved?" (FDA does not approve health care providers, including laboratories; registration does not denote approval); FDA Compliance Program 7348.808 (GLP inspections of nonclinical laboratories). https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved (accessed 2026-09-03)
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.
Pharmacology (Efficacy) Studies Replicate unknown pathological models and Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
SMC Laboratories, Inc. has established a disease models using patented mouse technologies.
The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project.
Their collaborative approach allows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc. (Labcorp Drug Development)
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements.
All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials.
For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
PhoenixBio Co., Ltd. offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to–drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides a seamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offers an integrated evaluation analysis covering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics.
For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.
Japanese
